MMR vaccine and autism: an update of the scientific evidence.

Abstract:

:An hypothesis published in 1998 suggested that measles-mumps-rubella vaccine may cause autism as a result of persistent measles virus infection of the gastrointestinal tract. Results of early studies were not supportive and in 2001 a review by the Institute of Medicine concluded that the evidence favors the rejection of a causal relationship at the population level between measles-mumps-rubella vaccine and autistic spectrum disorder. Studies published since the Institute of Medicine report have continued not to find an increased risk of autistic spectrum disorder associated with measles-mumps-rubella. The vaccine also has not been found to be associated with a unique syndrome of developmental regression and gastrointestinal disorders. The evidence now is convincing that the measles-mumps-rubella vaccine does not cause autism or any particular subtypes of autistic spectrum disorder.

journal_name

Expert Rev Vaccines

authors

DeStefano F,Thompson WW

doi

10.1586/14760584.3.1.19

keywords:

subject

Has Abstract

pub_date

2004-02-01 00:00:00

pages

19-22

issue

1

eissn

1476-0584

issn

1744-8395

pii

ERV030104

journal_volume

3

pub_type

杂志文章,评审
  • Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.

    abstract::Streptococcus pneumoniae, the most common cause of community-acquired pneumonia, remains a major cause of morbidity and mortality worldwide. The presence of chronic respiratory illness is a major risk factor for pneumonia, and smoking (the most common cause of chronic obstructive pulmonary disease) is also an importan...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.176

    authors: Vila-Corcoles A,Ochoa-Gondar O

    更新日期:2012-02-01 00:00:00

  • Generating humoral immune memory following infection or vaccination.

    abstract::The production of long-lived, high-affinity antibodies forms the basis of many successful vaccination strategies. Although much is known of the proteins and pathways of the immune system that lead to the production of these antibodies, there are also many processes that remain unexplained or poorly explained. Some vac...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.103

    authors: Randall KL

    更新日期:2010-09-01 00:00:00

  • CpG DNA as a vaccine adjuvant.

    abstract::Synthetic oligodeoxynucleotides containing unmethylated CpG motifs act as immune adjuvants, accelerating and boosting antigen-specific antibody responses by up to 500-fold. CpG motifs promote the production of T-helper 1 and pro-inflammatory cytokines and induce the maturation/activation of professional antigen-presen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.2.305

    authors: Klinman DM

    更新日期:2003-04-01 00:00:00

  • Expanding access to non-traditional vaccines: a perspective from Indonesia.

    abstract::In addition to the use of traditional vaccines in the National Immunization Program, the introduction: of additional vaccines in Indonesia appears to be important to further reduce rates of childhood mortality. However, it typically takes at least two decades for additional vaccines to be introduced into the National ...

    journal_title:Expert review of vaccines

    pub_type: 社论

    doi:10.1586/14760584.2014.944165

    authors: Suwantika AA,Postma MJ

    更新日期:2014-12-01 00:00:00

  • Ebola virus vaccines: an overview of current approaches.

    abstract::Ebola hemorrhagic fever is one of the most fatal viral diseases worldwide affecting humans and nonhuman primates. Although infections only occur frequently in Central Africa, the virus has the potential to spread globally and is classified as a category A pathogen that could be misused as a bioterrorism agent. As of t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.885841

    authors: Marzi A,Feldmann H

    更新日期:2014-04-01 00:00:00

  • Development of Group A streptococcal vaccines: an unmet global health need.

    abstract::Group A Streptococcus (GAS) infections are a significant global cause of morbidity and mortality. GAS diseases disproportionally affect those living in conditions characterized by poverty and social injustice, in both developing countries and in marginalized populations of industrialized nations. In Australia and New ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1116946

    authors: Sheel M,Moreland NJ,Fraser JD,Carapetis J

    更新日期:2016-01-01 00:00:00

  • 3rd Global Vaccine Congress.

    abstract::Singapore was the location of the 3rd Global Vaccine Congress on 4-6 October 2009, and it provided a suitable place for sharing a range of developments, concepts and challenges associated with vaccines. One of the major goals of this meeting was to present a broad and balanced program of research, development, product...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/erv.09.147

    authors: Kyd JM

    更新日期:2010-01-01 00:00:00

  • Chinese vaccine products go global: vaccine development and quality control.

    abstract::Through the continuous efforts of several generations, China has become one of the few countries in the world that is capable of independently addressing all the requirements by the Expanded Program on Immunization. Regulatory science is applied to continuously improve the vaccine regulatory system. Passing the prequa...

    journal_title:Expert review of vaccines

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14760584.2015.1012503

    authors: Xu M,Liang Z,Xu Y,Wang J

    更新日期:2015-05-01 00:00:00

  • Pediatric combined formulation DTaP-IPV/Hib vaccine.

    abstract::Combination vaccines have been used for many years in the USA as part of the primary infant immunization series. However, the current program still requires up to 24 injections by 18 months of age. The Advisory Committee on Immunization Practices in the USA recommends the use of combination vaccines whenever possible....

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.59

    authors: White C,Halperin SA,Scheifele DW

    更新日期:2009-07-01 00:00:00

  • Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.

    abstract::Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1176533

    authors: Vici P,Pizzuti L,Mariani L,Zampa G,Santini D,Di Lauro L,Gamucci T,Natoli C,Marchetti P,Barba M,Maugeri-Saccà M,Sergi D,Tomao F,Vizza E,Di Filippo S,Paolini F,Curzio G,Corrado G,Michelotti A,Sanguineti G,Giordano A

    更新日期:2016-10-01 00:00:00

  • Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination:a meta-analysis.

    abstract:BACKGROUND:Despite high 1-dose vaccination coverage, breakthrough varicella infections still occur. Therefore, 2-dose vaccination is recommended to enhance the immune response to the virus. However, the reported incremental vaccine effectiveness (VE) of 2-dose vaccination varies widely among studies. METHODS:To determ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14760584.2018.1433999

    authors: Yin M,Xu X,Liang Y,Ni J

    更新日期:2018-04-01 00:00:00

  • Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees.

    abstract::Interview by Jenaid Rees, Commissioning Editor Jeffrey Schlom obtained his PhD from Rutgers University (NJ, USA). After obtaining his PhD, he worked at Columbia University (NY, USA) before moving in 1973 to the National Cancer Institute, National Institutes of Health (MD, USA). Since then he has served as the Chief of...

    journal_title:Expert review of vaccines

    pub_type: 传,历史文章,面试

    doi:10.1586/14760584.2013.836913

    authors: Schlom J

    更新日期:2013-10-01 00:00:00

  • Current challenges for cancer vaccine adjuvant development.

    abstract:INTRODUCTION:Although much progress has been made in the last decade(s) toward development of effective cancer vaccines, there are still important obstacles to therapeutic successes. New generations of cancer vaccines will benefit from a combination adjuvant approach that targets multiple branches of the immune respons...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1434000

    authors: Bowen WS,Svrivastava AK,Batra L,Barsoumian H,Shirwan H

    更新日期:2018-03-01 00:00:00

  • T-cell immunity generated by recombinant adenovirus vaccines.

    abstract::Recombinant adenovirus vaccines show great promise for generating protective immunity against infectious agents and tumors. Our studies have identified several interesting biological features of the adenovirus vector that influence the T-cell response. Notably, we have demonstrated that following immunization with ade...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.3.347

    authors: Yang TC,Millar JB,Grinshtein N,Bassett J,Finn J,Bramson JL

    更新日期:2007-06-01 00:00:00

  • Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

    abstract::Pneumococcal disease is a major health problem worldwide. Large, rapid declines in overall invasive pneumococcal disease and mucosal disease in children, reductions in vaccine-type disease in unvaccinated children and adults (indirect effects) and significant drops in antibiotic-resistant infections were observed afte...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.9.1367

    authors: Dinleyici EC,Yargic ZA

    更新日期:2008-11-01 00:00:00

  • DNA-launched live-attenuated vaccines for biodefense applications.

    abstract::A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant pla...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1175943

    authors: Pushko P,Lukashevich IS,Weaver SC,Tretyakova I

    更新日期:2016-09-01 00:00:00

  • Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century.

    abstract::The epidemiology of meningococcal disease in Europe since 1945 has shown fluctuations in incidence, serogroup distribution and case-fatality rate. Outbreaks and epidemics driven by the introduction of new virulent strains into Europe have occurred unpredictably. Epidemics associated with serogroups A and B have occurr...

    journal_title:Expert review of vaccines

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/erv.11.117

    authors: Kriz P,Wieffer H,Holl K,Rosenlund M,Budhia S,Vyse A

    更新日期:2011-10-01 00:00:00

  • Controlling pertussis: how can we do it? A focus on immunization.

    abstract:INTRODUCTION:Pertussis is a highly contagious disease of the respiratory tract which is caused by the bacterium Bordetella pertussis and is most severe in those <1 year of age. A vaccine against pertussis, introduced in the 1950's, led to a significant decrease in incidence of the disease, but recent increases in outbr...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1445530

    authors: Martinón-Torres F,Heininger U,Thomson A,Wirsing von König CH

    更新日期:2018-04-01 00:00:00

  • An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

    abstract::With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In th...

    journal_title:Expert review of vaccines

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14760584.2013.811188

    authors: Fox CB,Haensler J

    更新日期:2013-07-01 00:00:00

  • Rotavirus vaccine-derived shedding and viral reassortants.

    abstract::EVALUATION OF: Donato CM, Ch’ng LS, Boniface KF et al. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J. Infect. Dis. 206(3), 377–383 (2012).Two live, attenuated rotavirus vaccines, RotaTeq(®) (Merck) and Rotarix(®) (GlaxoSmithKline), have been use...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.12.114

    authors: Bowen MD,Payne DC

    更新日期:2012-11-01 00:00:00

  • TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.

    abstract::Vaccination has been a successful tool in the protection against many infectious diseases, and recent advances in biotechnology have created new techniques and strategies to produce safe and efficacious vaccines for human use. However, developing a protective vaccine against malaria has been a challenge. In this artic...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.60

    authors: Coban C,Horii T,Akira S,Ishii KJ

    更新日期:2010-07-01 00:00:00

  • Virus-like particles as universal influenza vaccines.

    abstract::Current influenza vaccines are primarily targeted to induce immunity to the influenza virus strain-specific hemagglutinin antigen and are not effective in controlling outbreaks of new pandemic viruses. An approach for developing universal vaccines is to present highly conserved antigenic epitopes in an immunogenic con...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.70

    authors: Kang SM,Kim MC,Compans RW

    更新日期:2012-08-01 00:00:00

  • Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch.

    abstract::The skin is an attractive target for vaccine delivery. Adjuvants and antigens delivered into the skin can result in potent immune responses and an unmatched safety profile. The heat-labile enterotoxin (LT) from Escherichia coli, which acts both as antigen and adjuvant, has been shown to be delivered to human skin effi...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.5.809

    authors: Glenn GM,Flyer DC,Ellingsworth LR,Frech SA,Frerichs DM,Seid RC,Yu J

    更新日期:2007-10-01 00:00:00

  • Assessing readiness to implement routine immunization among patent and proprietary medicine vendors in Kano, Nigeria: a theory-informed cross-sectional study.

    abstract:BACKGROUND:Patent and proprietary medicine vendors (PPMVs) are widespread in communities and can potentially be used to expand access to routine immunization especially in underserved areas. In this study, we aimed to assess their readiness to implement routine immunization in Kano, Nigeria and identify factors associa...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1750379

    authors: Adamu AA,Gadanya MA,Jalo RI,Uthman OA,Nnaji CA,Bello IW,Wiysonge CS

    更新日期:2020-04-01 00:00:00

  • Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations.

    abstract::Introduction: Precision medicine describes the customization of healthcare tailored to the individual patient. Generally, vaccines are considered as public health tools rather than from the individual patient perspective. However, adult vaccination programs in particular should consider many different factors, at the ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1607303

    authors: Park SB,Kim HJ,Cheong HJ

    更新日期:2019-06-01 00:00:00

  • Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

    abstract::Lipopolysaccharide (LPS), a dominant component of the Gram-negative bacterial outer membrane, is a strong activator of the innate immune system, and thereby an important determinant in the adaptive immune response following bacterial infection. This adjuvant activity can be harnessed following immunization with bacter...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1026808

    authors: Zariri A,van der Ley P

    更新日期:2015-06-01 00:00:00

  • Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.

    abstract::Over recent years great attention has been directed to the discovery of novel antigens from Bacillus anthracis, because of the potential of its spores in the development of weapons for mass destruction. Substantial effort has been directed to the identification and immunochemical evaluation of glycans that might be us...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.924404

    authors: Adamo R

    更新日期:2014-07-01 00:00:00

  • In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.

    abstract:INTRODUCTION:Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of l...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1599286

    authors: Berkhout A,Clark JE,Wen SC

    更新日期:2019-05-01 00:00:00

  • Fluzone® High-Dose Influenza Vaccine.

    abstract:INTRODUCTION:Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1254044

    authors: Robertson CA,DiazGranados CA,Decker MD,Chit A,Mercer M,Greenberg DP

    更新日期:2016-12-01 00:00:00

  • Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.

    abstract::Infections of humans with Bacillus anthracis are an issue with respect to the biothreat both to civilians and military personnel, infections of individuals by infected livestock in endemic regions and, recently, infections of intravenous drug users injecting anthrax-contaminated heroin. Existing vaccination regimens a...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.981533

    authors: Altmann DM

    更新日期:2015-03-01 00:00:00